LEADING THE EFFORT IN CLINICAL TRANSLATION
A fundamental shift has taken place in our understanding of TGF-β biology which has significant implications for how we treat TGF-β-driven diseases.
Venn Therapeutics is a precision medicine company with a broad platform of scientific inquiry targeting cutting edge immuno-oncology (IO). We are developing a pipeline of novel, best-in-class agents that precisely and safely target key mechanisms of cancer, fibrosis and NASH.
FIRST-IN-CLASS
Integrin-mediated activation of TGF-β is at the root of resistance to therapies in the cancer tumor micro-environment, fibrosis, and NASH.
Our lead asset, VTX-001, is a monoclonal antibody that targets integrin avβ8 and has shown single-agent activity in multiple preclinical cancer models. VTX-001 has demonstrated promising efficacy and superior potency compared to known TGF-β inhibitors and a clean safety profile in preclinical trials.
A WORLD WITHOUT CANCER
Our mission is to contribute to a world without cancer.
Our goal is to become the preeminent oncology franchise for pharmaceutical companies seeking the most promising advances in immuno-oncology, and to contribute to making that vision a reality.
C6D4 called VTX-001. Cryo-EM Reveals Integrin-Mediated TGF-b Activation without Release from Latent TGF-b, Nishimura et.al